Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus
Belimumab (Benlysta) inhibits the B-lymphocyte simulator, and thus inhibits B cells, which are believed to play an important role in the pathophysiology of systematic lupus erythematosus (SLE). It is indicated, in addition to standard therapy, for reducing disease activity in adult patients with act...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2020, June 2020
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Belimumab (Benlysta) inhibits the B-lymphocyte simulator, and thus inhibits B cells, which are believed to play an important role in the pathophysiology of systematic lupus erythematosus (SLE). It is indicated, in addition to standard therapy, for reducing disease activity in adult patients with active, autoantibody-positive SLE. This submission relates to belimumab subcutaneous (SC) injection, 200 mg/mL weekly formulation. The submitted price is $421.79 per 200 mg. At the recommended dosage of 200 mg weekly, the average annual cost is $21,933 per patient. Belimumab was previously reviewed by CADTH for the IV infusion. CADTH Canadian Drug Expert Committee (CDEC) recommended belimumab IV not be reimbursed because its clinical benefit was uncertain and its cost-effectiveness could not be adequately assessed |
|---|---|
| Physical Description: | 1 PDF file (29 pages) illustrations |